达格列净用于合并急性器官功能障碍的危重患者:DEFENDER随机临床试验
DEFENDER为多中心、随机、开放标签临床试验,在巴西22个ICU纳入非计划入ICU且至少存在1个器官功能障碍(呼吸、心血管或肾脏)的507例危重患者,随机接受达格列净10 mg加标准治疗(n=248)或单纯标准治疗(n=259),最长14天或至ICU出院。主要终点为28天内医院死亡、启动肾脏替代治疗和ICU住院时长的分层复合终点,采用win ratio法分析,win ratio为1.01(95%CI 0.90-1.13;P=0.89)。所有次要终点中获益概率最高为0.90,对应肾脏替代治疗使用:达格列净组27例(10.9%)vs 对照组39例(15.1%)。作者结论认为加用达格列净未改善临床结局,但置信区间宽,不能排除相关获益或危害。
要点
- 在急性器官功能障碍的危重患者中,标准治疗加用达格列净10 mg未改善主要分层复合终点(win ratio 1.01,95%CI 0.90-1.13;P=0.89)。
- 肾脏替代治疗使用为次要终点中获益概率最高者(0.90):达格列净组27例(10.9%)vs 对照组39例(15.1%)。
- 研究对象为非计划入ICU且至少1个器官功能障碍(呼吸、心血管或肾脏)者,39.6%因疑似感染入ICU,入ICU至随机中位时间1天(IQR 0-1)。
- 作者结论指出置信区间宽,不能排除达格列净的相关获益或危害。
适用人群与场景
- 非计划入ICU且至少存在1个器官功能障碍(呼吸、心血管或肾脏)的危重患者。
- 共507例随机:达格列净组248例,对照组259例;平均年龄63.9岁(SD 15),女性46.9%,39.6%因疑似感染入ICU。
- 入ICU至随机中位时间1天(IQR 0-1)。
处置流程与药物剂量
- 达格列净10 mg加标准治疗,最长14天或至ICU出院,以先发生者为准(干预组n=248)。
- 对照组仅接受标准ICU治疗(n=259)。
研究设计与关键结果
- 多中心、随机、开放标签临床试验,在巴西22个ICU开展,2022年11月22日至2023年8月30日入组,随访至2023年9月27日。
- 主要终点为28天内医院死亡、启动肾脏替代治疗和ICU住院时长的分层复合终点,win ratio法分析:达格列净组win ratio 1.01(95%CI 0.90-1.13;P=0.89)。
- 次要终点包括分层终点的各单项组分、无器官支持天数、ICU和住院时长,采用贝叶斯回归模型评估。
- 所有次要终点中获益概率最高为0.90,对应肾脏替代治疗使用:达格列净组27例(10.9%)vs 对照组39例(15.1%)。
证据类型、等级与局限
- 证据类型:多中心随机开放标签临床试验(RCT)。
- 局限:原文结论指出置信区间宽,不能排除达格列净的相关获益或危害。
对床旁实践的改变
- 对于非计划入ICU且至少1个器官功能障碍的危重患者,在标准治疗基础上加用达格列净10 mg未改善临床结局,不支持以改善预后为目的常规加用。
- 作者结论认为置信区间宽,不能排除达格列净的相关获益或危害,临床决策需结合个体情况。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors improve outcomes in patients with type 2 diabetes, heart failure, and chronic kidney disease, but their effect on outcomes of critically ill patients with organ failure is unknown.
OBJECTIVE: To determine whether the addition of dapagliflozin, an SGLT-2 inhibitor, to standard intensive care unit (ICU) care improves outcomes in a critically ill population with acute organ dysfunction.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, open-label, clinical trial conducted at 22 ICUs in Brazil. Participants with unplanned ICU admission and presenting with at least 1 organ dysfunction (respiratory, cardiovascular, or kidney) were enrolled between November 22, 2022, and August 30, 2023, with follow-up through September 27, 2023.
INTERVENTION: Participants were randomized to 10 mg of dapagliflozin (intervention, n = 248) plus standard care or to standard care alone (control, n = 259) for up to 14 days or until ICU discharge, whichever occurred first.
MAIN OUTCOMES AND MEASURES: The primary outcome was a hierarchical composite of hospital mortality, initiation of kidney replacement therapy, and ICU length of stay through 28 days, analyzed using the win ratio method. Secondary outcomes included the individual components of the hierarchical outcome, duration of organ support-free days, ICU, and hospital stay, assessed using bayesian regression models.
RESULTS: Among 507 randomized participants (mean age, 63.9 [SD, 15] years; 46.9%, women), 39.6% had an ICU admission due to suspected infection. The median time from ICU admission to randomization was 1 day (IQR, 0-1). The win ratio for dapagliflozin for the primary outcome was 1.01 (95% CI, 0.90 to 1.13; P = .89). Among all secondary outcomes, the highest probability of benefit found was 0.90 for dapagliflozin regarding use of kidney replacement therapy among 27 patients (10.9%) in the dapagliflozin group vs 39 (15.1%) in the control group.
CONCLUSION AND RELEVANCE: The addition of dapagliflozin to standard care for critically ill patients and acute organ dysfunction did not improve clinical outcomes; however, confidence intervals were wide and could not exclude relevant benefits or harms for dapagliflozin.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05558098.
参考来源
- Tavares CAM, Azevedo LCP, Rea-Neto Á, et al. Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction: The DEFENDER Randomized Clinical Trial. JAMA. 2024. PMID: 38873723. doi:10.1001/jama.2024.10510
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。